サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1720938

がん分子診断薬の世界市場：がんタイプ別、製品タイプ別、場所別の市場予測 - エグゼクティブコンサルタントガイド付き（2025年～2029年）- 人工知能の影響

Molecular Diagnostics for Cancer. Markets Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides and Impact of Artificial Intelligence. 2025 to 2029

出版日
ページ情報
英文 448 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
がん分子診断薬の世界市場：がんタイプ別、製品タイプ別、場所別の市場予測 - エグゼクティブコンサルタントガイド付き（2025年～2029年）- 人工知能の影響
出版日: 2025年05月05日
発行: Howe Sound Research
ページ情報: 英文 448 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん分子診断薬は再び成長軌道に乗っています。そしてあらゆるセグメントで成長が加速しています。業界を再構築しつつある新しい市場セグメントであるがんコンパニオン診断薬を特別収録しました。140以上の企業プロファイルが掲載されています。様々な動向が市場の成長と企業の評価を押し上げています。

その動向は以下の通り：

  • 個別化医療
  • ファーマコゲノミクス
  • リキッドバイオプシー
  • 最小残存病変検査
  • 大きな市場を持つ新しい経済圏の出現
  • 新しいインテリジェント診断検査に取って代わられつつある医師による診断

特にコンパニオン診断におけるエキサイティングな技術開発は、単一の検査施設が世界中の患者を対象とする、ダイナミックで成長し、進化する世界市場の到来を予感させます。

当レポートには、カスタマイズ、特定セグメントへのブレークアウト、アシスタンス、サポートが無料で含まれています。

当レポートには、18の国と4つの地域の詳細な内訳が含まれています。レポート購入者は、世界のどの国の詳細なブレイクアウトも入手可能です。

当レポートは、世界のがん分子診断薬市場について調査し、市場の概要とともに、がんタイプ別、製品タイプ別、場所別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

  • 分子診断とは何か
  • 診断革命
  • 市場定義
  • 調査手法
  • 視点：ヘルスケアとIVD業界

第3章 市場概要

  • 市場セグメント
  • 業界構造

第4章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計測、自動化、診断の動向

第5章 分子診断の最近の動向

第6章 主要企業のプロファイル

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Acuamark Diagnostics
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Aethlon Medical
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • BillionToOne
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bristol-Myers Squibb
  • Burning Rock
  • C2i Genomics
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • Celemics
  • CellCarta
  • CellMax Life
  • Cepheid（Danaher）
  • Charles River Laboratories
  • Circulogene
  • Cizzle Biotech
  • Clearbridge Biomedics
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Dxcover
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Erythra
  • Eurofins Scientific
  • Exact Sciences
  • Fabric Genomics
  • Fluxion Biosciences（Cell Microsystems）
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • Fyr Diagnostics
  • GeneDx Holdings
  • GeneFirst Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HTG Molecular Diagnostics
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • J&J Innovative Medicine
  • Lucence Health
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Metabiomics Corp
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics
  • Nanostring
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • NGeneBio
  • Novogene
  • Oncimmune
  • Oncocyte
  • OncoDNA
  • Oncohost
  • OraLiva
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Personalis
  • Perthera
  • PGDx（Labcorp）
  • Precipio
  • PrecisionMed
  • Predicine
  • Predictive Oncology
  • Prenetics
  • Promega
  • Qiagen
  • QuidelOrtho
  • Rarecells SAS
  • RareCyte
  • Revvity
  • Roche Diagnostics
  • Screencell
  • Sherlock Biosciences
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Singulomics
  • SkylineDx
  • Standard BioTools
  • Stilla Technologies
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific
  • Todos Medical
  • Ultima Genomics
  • Variantyx
  • Vela Diagnostics
  • Veracyte
  • VolitionRX
  • Vortex Biosciences
  • Zhejiang Orient Gene Biotech

第7章 世界のがん分子診断薬市場

  • がん分子診断薬-国別世界市場概要
  • がんタイプ別世界市場- 概要
  • 製品タイプ別世界市場- 概要
  • 場所別世界市場- 概要

第8章 がんタイプ別世界市場

  • 乳がん
  • 大腸がん
  • 子宮頸がん
  • 肺がん
  • 前立腺
  • メラノーマがん
  • 血液がん
  • コンパニオン診断薬開発
  • その他

第9章 製品タイプ別世界市場

  • 機器
  • 試薬
  • ソフトウェアおよびサービス

第10章 地域別世界市場

  • 臨床検査室
  • 製薬
  • 研究

第11章 がん治療と臨床試験

  • FDA承認（年別・申請別）
  • 臨床試験開始
  • がん治療の普及率

第12章 付録

図表

Table of Tables

  • Table 1: Clinical Laboratory Departments and Segments
  • Table 2: Laboratory Management Focus - Different Approaches
  • Table 3: Key Segmentation Variables Going Forward
  • Table 4: Five Factors Driving Growth
  • Table 5: Factors Limiting Growth
  • Table 6: Seven Key Diagnostic Laboratory Technology Trends
  • Table 7: Global MDx Cancer Market by Region
  • Table 8: Global Market by Cancer Type
  • Table 9: Global Market by Product Type
  • Table 10: Global Market by Place
  • Table 11: MDx Breast Cancer by Country
  • Table 12: MDx Colorectal Cancer by Country
  • Table 13: Cervical Cancer Testing by Country
  • Table 14: Lung Cancer Testing by Country
  • Table 15: Prostate Testing by Country
  • Table 16: Melanoma Cancer Testing by Country
  • Table 17: MDx Blood by Country
  • Table 18: MDx Companion Dx Development by Country
  • Table 19: MDx Other Cancer Testing by Country
  • Table 20: MDx Instruments by Country
  • Table 21: MDx Reagents by Country
  • Table 22: Software and Services by Country
  • Table 23: MDx Clinical Laboratory by Country
  • Table 24: MDx Pharmaceutical by Country
  • Table 25: Research by Country
  • Table 26: Clinical Lab Fee Schedule
  • Table 27: The Most Common Assays
  • Table 28: Largest Revenue Assays

Table of Figures

  • Figure 1: Global Health Spending
  • Figure 2: The Lab Test Pie
  • Figure 3: The Changing Age of The World's Population
  • Figure 4: Health Care Consumption by Age
  • Figure 5: Cancer Incidence - Age at Diagnosis
  • Figure 6: Centralized vs. Decentralized Laboratory Service
  • Figure 7: A Highly Multiplexed Syndromic Testing Unit
  • Figure 8: The Real Cost to Sequence the Human Genome
  • Figure 9: The Codevelopment Process
  • Figure 10: Comparing MDx Diagnostic and Traditional Testing
  • Figure 11: Global Market Shares Base Year
  • Figure 12: MDx Market by Cancer - Base vs. Final
  • Figure 13: Cancer Market Base Year
  • Figure 14: Cancer Market Final Year
  • Figure 15: MDx Cancer Share by Year
  • Figure 16: MDx Cancer Segment Growth Rates
  • Figure 17: MDx Market by Product - Base vs. Final
  • Figure 18: Product Market Base Year
  • Figure 19: Product Market Final Year
  • Figure 20: MDx Product Share by Year
  • Figure 21: MDx Product Segment Growth Rates
  • Figure 22: MDx Market by Place - Base vs. Final
  • Figure 23: Place Market Base Year
  • Figure 24: Place Market Final Year
  • Figure 25: MDx Place Share by Year
  • Figure 26: MDx Place Segment Growth Rates
  • Figure 27: Breast Cancer Testing Growth
  • Figure 28: Colorectal Cancer Testing Growth
  • Figure 29: Cervical Cancer Testing Growth
  • Figure 30: Lung Cancer Testing Growth
  • Figure 31: Prostate Testing Growth
  • Figure 32: Melanoma Cancer Testing Growth
  • Figure 33: Blood Testing Growth
  • Figure 34: Companion Dx Development Growth
  • Figure 35: Other Cancer Testing Growth
  • Figure 36: Instruments Growth
  • Figure 37: Reagents Growth
  • Figure 38: Software and Services Growth
  • Figure 39: Clinical Laboratory Growth
  • Figure 40: Pharmaceutical Growth
  • Figure 41: Research Growth
  • Figure 42: FDA Approvals by Year and Application
  • Figure 43: Clinical Trials for Oncology by Year
  • Figure 44: Pie Chart of Prevalence of Cancer Treatments
目次

OVERVIEW:

Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 140 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • minimal residual disease testing
  • emergence of new economies with large markets
  • physician diagnostics being displaced by new intelligent diagnostic tests

Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

  • 1.1. Cancer MDx - Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors
  • 1.4. Impact of Artificial Intelligence on Cancer MDx

2. Introduction and Market Definition

  • 2.1. What are Molecular Diagnostics?
  • 2.2. The Diagnostics Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

  • 3.1. Market Segments
    • 3.1.1. Traditional Market Segmentation
    • 3.1.2. Laboratory Focus and Segmentation
  • 3.2. Industry Structure
    • 3.2.1. Hospital Testing Share
    • 3.2.2. Economies of Scale
    • 3.2.3. Physician Office Lab's
    • 3.2.4. Physician's and POCT

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. New Diagnostics Create New Markets
    • 4.1.2. New Roles for Diagnostics
    • 4.1.3. Aging Effect
    • 4.1.4. Expanding the Pharmaceutical Toolbox
    • 4.1.5. Regulatory Retreat
  • 4.2. Factors Limiting Growth
    • 4.2.1. Falling Prices
    • 4.2.2. Lower Costs
    • 4.2.3. Wellness has a Downside
  • 4.3. Instrumentation, Automation and Diagnostic Trends
    • 4.3.1. Traditional Automation and Centralization
    • 4.3.2. The New Automation, Decentralization and Point Of Care
    • 4.3.3. Instruments Key to Market Share
    • 4.3.4. Bioinformatics Plays a Role
    • 4.3.5. PCR Takes Command
    • 4.3.6. Next Generation Sequencing Fuels a Revolution
    • 4.3.7. NGS Impact on Pricing
    • 4.3.8. Whole Genome Sequencing, A Brave New World
    • 4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
    • 4.3.10. Shifting Role of Diagnostics
    • 4.3.11. Multiplexing and Foundation One
    • 4.3.12. Pharmacogenomics Technology
    • 4.3.13. Gene Editing and Gene Therapy

5. Molecular Diagnostics Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Guardant Health Guardant360 Tissue
  • 5.3. AccuStem Sciences & EmeritusDx partner for Lung Cancer Screening
  • 5.4. LetsGetChecked LaunchesHereditary Cancer Test
  • 5.5. Guardant Health's Colorectal Test New Status
  • 5.6. Tempus xT CDx
  • 5.7. OneCell Diagnostics Raises $16M
  • 5.8. A. Menarini to use Nucleix Bladder Cancer Test
  • 5.9. Foundation Medicine, Repare Therapeutics to Develop CDx
  • 5.10. NHS Declines to Accelerate Grail Galleri Implementation
  • 5.11. GeneDx Sees Growing Demand for Testing
  • 5.12. Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
  • 5.13. ClearNote Health Expands Into Immunotherapy Monitoring
  • 5.14. Foundation Medicine to Collaborate on CDx for Lung Cancer
  • 5.15. Qiagen and Myriad Genetics Partner to Develop Cancer CDx
  • 5.16. Lung Cancer Data Heralds Shift for Hummingbird Dx
  • 5.17. PamGene Awarded Euro-7.5M for Immunotherapy Test
  • 5.18. Grail Cancer Test Faces New Clinical Questions
  • 5.19. Freenome Acquires Cancer Dx Firm Oncimmune
  • 5.20. Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
  • 5.21. Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
  • 5.22. Digital Pathology Meets Cancer Sequencing
  • 5.23. Exact Sciences Preps Expanded Oncology Portfolio
  • 5.24. Qiagen Details Oncology Plans for Digital PCR Platform
  • 5.25. Sema4 Exiting Reproductive Health Screening
  • 5.26. Thermo Fisher Introduces Cancer Profiling Assay
  • 5.27. Genomic Test IDs Cysts Likely to Progress to Cancer
  • 5.28. Naveris to Commercialize Virus-Related Cancer Tests
  • 5.29. Larger Liquid Biopsy Panels Loom
  • 5.30. Halo Diagnostics to Offer Genomic Profiling Tests
  • 5.31. BillionToOne Raises $125M
  • 5.32. Local Cancer Genomic Profiling Options Grow
  • 5.33. German MDx Firm Mainz Biomed Raises $10M in IPO
  • 5.34. Guardant Health Q3 Revenues Up 27 Percent
  • 5.35. BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
  • 5.36. Nucleix to Invest in Early-Stage Lung Cancer Dx
  • 5.37. Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
  • 5.38. Grail Gets Approval for Galleri Multicancer Test
  • 5.39. Finnish Firms to Form Point-of-Care Testing Firm
  • 5.40. Datar Cancer Genetics Expands to Dx and Screening
  • 5.41. HTG Molecular Diagnostics: HTG Transcriptome Panel
  • 5.42. PacBio's Omniome Acquisition Shortens Path to Clinical
  • 5.43. Invitae to Acquire Genosity for $200M
  • 5.44. Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
  • 5.45. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
  • 5.46. Natera Revenues Grow 35 Percent
  • 5.47. AnchorDx Closes $40M Financing Round
  • 5.48. Exact Sciences Strategy for End-to-End Cancer Testing
  • 5.49. Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

6. Profiles of Key MDx Companies

  • 6.1. 10x Genomics, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. AccuraGen Inc.
  • 6.4. Acuamark Diagnostics
  • 6.5. Adaptive Biotechnologies
  • 6.6. Admera Health, LLC
  • 6.7. Aethlon Medical
  • 6.8. Agilent
  • 6.9. Amoy Diagnostics Co., Ltd.
  • 6.10. Anchor Dx
  • 6.11. ANGLE plc
  • 6.12. ARUP Laboratories
  • 6.13. AVIVA Systems Biology
  • 6.14. Baylor Miraca Genetics Laboratories
  • 6.15. Beckman Coulter Diagnostics (Danaher)
  • 6.16. Becton, Dickinson and Company
  • 6.17. BGI Genomics Co. Ltd
  • 6.18. BillionToOne
  • 6.19. Bioarray Genetics
  • 6.20. Biocartis
  • 6.21. Biocept, Inc.
  • 6.22. Biodesix Inc.
  • 6.23. BioFluidica
  • 6.24. BioGenex
  • 6.25. BioIVT
  • 6.26. Biolidics Ltd
  • 6.27. bioMerieux Diagnostics
  • 6.28. Bioneer Corporation
  • 6.29. Bio-Rad Laboratories, Inc
  • 6.30. Bio-Reference Laboratories
  • 6.31. Bio-Techne
  • 6.32. Bioview
  • 6.33. Bristol-Myers Squibb
  • 6.34. Burning Rock
  • 6.35. C2i Genomics
  • 6.36. Cardiff Oncology
  • 6.37. Caris Molecular Diagnostics
  • 6.38. Castle Biosciences, Inc.
  • 6.39. Celemics
  • 6.40. CellCarta
  • 6.41. CellMax Life
  • 6.42. Cepheid (Danaher)
  • 6.43. Charles River Laboratories
  • 6.44. Circulogene
  • 6.45. Cizzle Biotech
  • 6.46. Clearbridge Biomedics
  • 6.47. Clinical Genomics
  • 6.48. Cytolumina Technologies Corp.
  • 6.49. Datar Cancer Genetics Limited
  • 6.50. Diagnologix LLC
  • 6.51. Diasorin S.p.A.
  • 6.52. Dxcover
  • 6.53. Element Biosciences
  • 6.54. Enzo Biochem
  • 6.55. Epic Sciences
  • 6.56. Epigenomics AG
  • 6.57. Erythra
  • 6.58. Eurofins Scientific
  • 6.59. Exact Sciences
  • 6.60. Fabric Genomics
  • 6.61. Fluxion Biosciences (Cell Microsystems)
  • 6.62. Freenome
  • 6.63. FUJIFILM Wako Diagnostics
  • 6.64. Fujirebio
  • 6.65. Fulgent Genetics
  • 6.66. Fyr Diagnostics
  • 6.67. GeneDx Holdings
  • 6.68. GeneFirst Ltd.
  • 6.69. Genetron Holdings
  • 6.70. GenomOncology
  • 6.71. GILUPI Nanomedizin
  • 6.72. Guardant Health
  • 6.73. HansaBiomed
  • 6.74. HTG Molecular Diagnostics
  • 6.75. iCellate
  • 6.76. ICON PLC
  • 6.77. Illumina
  • 6.78. Incell Dx
  • 6.79. Inivata
  • 6.80. INOVIQ
  • 6.81. Invitae Corporation
  • 6.82. Invivogen
  • 6.83. Invivoscribe
  • 6.84. J&J Innovative Medicine
  • 6.85. Lucence Health
  • 6.86. Lunglife AI Inc
  • 6.87. MDNA Life SCIENCES, Inc.
  • 6.88. MDx Health
  • 6.89. Menarini Silicon Biosystems
  • 6.90. Mesa Laboratories, Inc.
  • 6.91. Metabiomics Corp
  • 6.92. Millipore Sigma
  • 6.93. Miltenyi Biotec
  • 6.94. miR Scientific
  • 6.95. Myriad Genetics
  • 6.96. Nanostring
  • 6.97. NantHealth, Inc.
  • 6.98. Natera
  • 6.99. NeoGenomics
  • 6.100. NGeneBio
  • 6.101. Novogene
  • 6.102. Oncimmune
  • 6.103. Oncocyte
  • 6.104. OncoDNA
  • 6.105. Oncohost
  • 6.106. OraLiva
  • 6.107. Oxford Nanopore Technologies
  • 6.108. PamGene
  • 6.109. Panagene
  • 6.110. Personalis
  • 6.111. Perthera
  • 6.112. PGDx (Labcorp)
  • 6.113. Precipio
  • 6.114. PrecisionMed
  • 6.115. Predicine
  • 6.116. Predictive Oncology
  • 6.117. Prenetics
  • 6.118. Promega
  • 6.119. Qiagen
  • 6.120. QuidelOrtho
  • 6.121. Rarecells SAS
  • 6.122. RareCyte
  • 6.123. Revvity
  • 6.124. Roche Diagnostics
  • 6.125. Screencell
  • 6.126. Sherlock Biosciences
  • 6.127. Siemens Healthineers
  • 6.128. simfo GmbH
  • 6.129. Singlera Genomics Inc.
  • 6.130. Singular Genomics
  • 6.131. Singulomics
  • 6.132. SkylineDx
  • 6.133. Standard BioTools
  • 6.134. Stilla Technologies
  • 6.135. Sysmex Inostics
  • 6.136. Tempus Labs, Inc.
  • 6.137. Thermo Fisher Scientific
  • 6.138. Todos Medical
  • 6.139. Ultima Genomics
  • 6.140. Variantyx
  • 6.141. Vela Diagnostics
  • 6.142. Veracyte
  • 6.143. VolitionRX
  • 6.144. Vortex Biosciences
  • 6.145. Zhejiang Orient Gene Biotech

7. The Global Market for MDx Cancer

  • 7.1. MDx Cancer - Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Cancer Type - Overview
    • 7.2.1. Table - Global Market by Cancer Type
    • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Comparison
    • 7.2.3. Chart - Global Market by Cancer Type - Base Year
    • 7.2.4. Chart - Global Market by Cancer Type -Final Year
    • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
    • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
  • 7.3. Global Market by Product Type - Overview
    • 7.3.1. Table - Global Market by Product Type
    • 7.3.2. Chart - Global Market by Product Type - Base/Final Comparison
    • 7.3.3. Chart - Global Market by Product Type - Base Year
    • 7.3.4. Chart - Global Market by Product Type -Final Year
    • 7.3.5. Chart - Global Market by Product Type - Share by Year
    • 7.3.6. Chart - Global Market by Product Type - Segment Growth
  • 7.4. Global Market by Place - Overview
    • 7.4.1. Table - Global Market by Place
    • 7.4.2. Chart - Global Market by Place - Base/Final Comparison
    • 7.4.3. Chart - Global Market by Place - Base Year
    • 7.4.4. Chart - Global Market by Place -Final Year
    • 7.4.5. Chart - Global Market by Place - Share by Year
    • 7.4.6. Chart - Global Market by Place - Segment Growth

8. Global Market by Cancer Type

  • 8.1. MDx Breast Cancer
    • 8.1.1. Table Breast Cancer Testing - by Country
    • 8.1.2. Chart - Breast Cancer Testing Growth
  • 8.2. MDx Colorectal Cancer
    • 8.2.1. Table Colorectal Cancer Testing - by Country
    • 8.2.2. Chart - Colorectal Cancer Testing Growth
  • 8.3. MDx Cervical Cancer
    • 8.3.1. Table Cervical Cancer Testing - by Country
    • 8.3.2. Chart - Cervical Cancer Testing Growth
  • 8.4. MDx Lung Cancer
    • 8.4.1. Table Lung Cancer Testing - by Country
    • 8.4.2. Chart - Lung Cancer Testing Growth
  • 8.5. MDx Prostate
    • 8.5.1. Table Prostate Testing - by Country
    • 8.5.2. Chart - Prostate Testing Growth
  • 8.6. MDx Melanoma Cancer
    • 8.6.1. Table Melanoma Cancer Testing - by Country
    • 8.6.2. Chart - Melanoma Cancer Testing Growth
  • 8.7. MDx Blood
    • 8.7.1. Table Blood Testing - by Country
    • 8.7.2. Chart - Blood Testing Growth
  • 8.8. MDx Companion Dx Development
    • 8.8.1. Table Companion Dx Development - by Country
    • 8.8.2. Chart - Companion Dx Development Growth
  • 8.9. MDx Other Cancer
    • 8.9.1. Table Other Cancer Testing - by Country
    • 8.9.2. Chart - Other Cancer Testing Growth

9. Global Market by Product Type

  • 9.1. MDx Instruments
    • 9.1.1. Table Instruments - by Country
    • 9.1.2. Chart - Instruments Growth
  • 9.2. MDx Reagents
    • 9.2.1. Table Reagents - by Country
    • 9.2.2. Chart - Reagents Growth
  • 9.3. MDx Software and Services
    • 9.3.1. Table Software and Services - by Country
    • 9.3.2. Chart - Software and Services Growth

10. Global Market by Place

  • 10.1. MDx Clinical Laboratory
    • 10.1.1. Table Clinical Laboratory - by Country
    • 10.1.2. Chart - Clinical Laboratory Growth
  • 10.2. MDx Pharmaceutical
    • 10.2.1. Table Pharmaceutical - by Country
    • 10.2.2. Chart - Pharmaceutical Growth
  • 10.3. MDx Research
    • 10.3.1. Table Research - by Country
    • 10.3.2. Chart - Research Growth

11. Cancer Treatment and Trials

  • 11.1. FDA Approvals by Year and Application
  • 11.2. Clinical Trials Starts
  • 11.3. Prevalence of Cancer Treatments

12. Appendices

  • 12.1. United States Medicare System: Clinical Laboratory Fees Schedule
  • 12.2. The Most Used IVD Assays
  • 12.3. The Highest Grossing Assays
  • 12.4. FDA Approved Human Genetic Tests
  • 12.5. FDA Approved Pharmacogenomics Tests